Catalyst
Slingshot members are tracking this event:
Athersys (ATHX) Receives Special Protocol Assessment (SPA) From FDA Agreeing to Phase 3 Trial Design for MultiStem in Treatment of Ischemic Stroke Patients
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ATHX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda Agreement, Special Protocol Assessment, Phase 3 Masters-2, Multistem, Ischemic Stroke Patients
